BBPOS
25.5.2016 10:01:37 CEST | Business Wire | Press release
BBPOS has announced the launch of WisePadTM 2; advanced technology developed by innovative engineers. The WisePadTM 2 can be used in an integrated or semi-integrated POS environment as well as a stand-alone environment connecting to the payment processor or gateway via GPRS, 3G or Wi-Fi.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160525005100/en/
WisePadTM 2 reads EMV chip card, triple track magnetic stripe card, NFC card and has a secured PIN pad. Compact and lightweight at 3.7oz (105g), it is mobile and flexible. The WisePadTM 2 also has standard over-the-air features allowing both firmware updates and key injection that are essential in increasing operational efficiency as well as having a 2G/3G modem to allow direct connectivity to the network.
WisePadTM 2 complies with all major industrial security standards including PCI PTS v4.1 with SRED; EMV L1 & L2; EMV Contactless L1; VISA payWave; MasterCard PayPass; AMEX ExpressPay; Discover D-PAS; and MasterCard TQM.
WisePadTM 2 will be widely adopted as a mobile solution working with a smart device or as a stand-alone solution. It will also be a good alternative to conventional counter-top POS devices in countries which use Chip and PIN payment systems, such as China and in Europe. The non-NFC versions have been used at a number of key events and by merchants. For example, at the Dubai World Cup, customers had the flexibility and convenience of not waiting in long queues to purchase tickets and, instead, were able to use their debit or credit cards via roaming staff who were using tablets and WisePadTM .
WisePadTM 2 is the future of mPOS - delivering a cost effective solution with convenient updating and a wide range of applications. Please visit our website for more details.
BBPOS
www.bbpos.com
WisePadTM
2
http://bbpos.com/files/bbproducts/11-WP2_A4_Catalogue_20160523.pdf
About BBPOS
Founded in 2008, BBPOS is an mPOS solution provider headquartered in Hong Kong with regional offices in San Jose, Miami, London, Singapore and Shanghai. The business invented the mobile payment audio jack at a time when smart phones were in their infancy. Today, we are respected as a leading innovator, designer, and manufacturer of end-to-end mobile POS solutions, serving key sectors including mobile merchant, retail, hospitality, delivery, transport and government.
Our world-class engineering team has developed a family of innovative POS devices that deliver quality solutions while implementing the highest security standards. Our products are designed with the flexibility to securely manage any transaction, in any environment, anywhere in the world. In March 2016, mPOS tracker ranked BBPOS 6th among 212 global payment industry players with a high score of 70.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160525005100/en/
Contact:
BBPOS
Gloria Chan, +852-3907-0305
gloria.chan@bbpos.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom